Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis
Author
Abstract
Suggested Citation
DOI: 10.2165/11587360-000000000-00000
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.
- Lee R. Mobley & Thomas J. Hoerger & John S. Wittenborn & Deborah A. Galuska & Jaya K. Rao, 2006. "Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate," Medical Decision Making, , vol. 26(2), pages 194-206, March.
- Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.
- Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Dirk Mueller & Afschin Gandjour, 2008. "Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 113-135, July.
- Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
- Eberhard Wille & Jürgen Scholze & Eduardo Alegria & Claudio Ferri & Sue Langham & Warren Stevens & David Jeffries & Kerstin Uhl-Hochgraeber, 2011. "Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 205-218, June.
- Robert L. Herrick & Steven G. Buchberger & Robert M. Clark & Margaret Kupferle & Regan Murray & Paul Succop, 2012. "A Markov Model To Estimate Salmonella Morbidity, Mortality, Illness Duration, And Cost," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1169-1182, October.
- Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.
- Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring, 2017. "Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal," PharmacoEconomics, Springer, vol. 35(12), pages 1237-1255, December.
- Rachael Fleurence & Cynthia Iglesias & Jeanene Johnson, 2007. "The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis," PharmacoEconomics, Springer, vol. 25(11), pages 913-933, November.
- Afschin Gandjour, 2010. "A model to predict the cost‐effectiveness of disease management programs," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 697-715, June.
- Kurt Lippuner & Richard Pollock & Jayne Smith-Palmer & Thomas Meury & William Valentine, 2011. "A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland," Applied Health Economics and Health Policy, Springer, vol. 9(6), pages 403-417, November.
- Douglas Wolf & Thomas Gill, 2009. "Modeling transition rates using panel current-status data: How serious is the bias?," Demography, Springer;Population Association of America (PAA), vol. 46(2), pages 371-386, May.
- Smita Nayak & Mark S Roberts & Susan L Greenspan, 2012. "Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-7, March.
- Björn Stollenwerk & Afschin Gandjour & Markus Lüngen & Uwe Siebert, 2013. "Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 1035-1048, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:9:y:2011:i:4:p:259-273. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.